59.23 -0.02 (-0.04%)
After hours: 4:11PM EST
|Bid||58.25 x 1200|
|Ask||61.00 x 900|
|Day's Range||56.89 - 59.88|
|52 Week Range||36.03 - 64.94|
|Beta (3Y Monthly)||1.40|
|PE Ratio (TTM)||32.68|
|Earnings Date||Nov 12, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||57.00|
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") today announced that the Company has commenced dosing in a pilot clinical study to assess the unique characteristics of its fulvestrant product candidate, which has the potential to enhance estrogen receptor ("ER") inhibition and improve patient outcomes. The results of the pilot study will inform the design of the Company’s pivotal trial, which Eagle expects to commence in 2020.
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) shareholders might be concerned after seeing the share price drop 12% in the...
Eagle Pharmaceuticals, Inc. today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will pr
Mr. Braunstein joined the Board in 2016 and served on its Compensation Committee. “I am pleased to have had the opportunity to contribute to Eagle’s many accomplishments during my time on the Board,” Mr. Braunstein said.
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of -16.13% and -5.06%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
-- Net loss of $0.17 per basic and diluted share and adjusted non-GAAP net income of $0.27 per basic and $0.26 per diluted share in Q3 2019 --
Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (EGRX) today provided an update on the Company’s program for RYANODEX® (dantrolene sodium for injectable suspension) for the treatment of exertional heat stroke (“EHS”). Eagle is investigating RYANODEX for EHS in addition to current standard of care, which is comprised of body cooling and supportive measures.
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Our research shows that most of the stocks that smart money likes historically generate strong risk-adjusted returns. […]
Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Eagle Pharmaceuticals, Inc. today announced that the Company will release its 2019 third quarter financial results on Tuesday, November 12, 2019, before the market opens.
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Eagle...
Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (EGRX) today announced that its marketing partner SymBio Pharmaceuticals Limited (“SymBio”) has submitted a New Drug Application (“NDA”) for TREAKISYM ready-to-dilute (“RTD”) liquid formulation in Japan. The NDA covers all indications for which TREAKISYM is currently approved (low-grade non-Hodgkin’s lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia).
The goal of this article is to teach you how to use price to earnings ratios (P/E ratios). To keep it practical, we'll...
Zacks.com featured highlights include: Garmin, Eagle Pharmaceuticals, BMC Stock, SeaWorld and Zumiez
If you own shares in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) then it's worth thinking about how it contributes to...
The FDA approves Nabriva's (NBRV) new drug application for both intravenous and oral formulations of Xenleta to treat adult patients with community-acquired bacterial pneumonia.
Building up an investment case requires looking at a stock holistically. Today I've chosen to put the spotlight on...